Looking to leapfrog antibodies and RNAi, Sekar Kathiresan says gene editing approach to cut PCSK9 looks durable
JP Morgan isn’t typically a data conference. But there are always exceptions for data that could make or break a company, piquing the interest of potential investors and partners alike.
Data, for instance, like what Sekar Kathiresan is bringing to the virtual conference, showing that a one-time treatment with Verve Therapeutics’ base editor can keep PCSK9 levels low — thereby lowering LDL cholesterol, aka the bad kind — out to 6 months. In non-human primates.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.